Phase 1/2 × Interventional × Myelodysplastic-Myeloproliferative Diseases × Clear all
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled
NCT00245037 2017-09-27

Bu Flu TBI

OHSU Knight Cancer Institute

Phase 1/2 Completed
147 enrolled 19 charts
NCT00014495 2016-01-22

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
32 enrolled 9 charts
NCT00823524 2013-02-20

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Asan Medical Center

Phase 1/2 Completed
47 enrolled
NCT00006225 2012-06-06

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Northwestern University

Phase 1/2 Completed
NCT00064311 2012-03-08

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
NCT00089037 2011-07-15

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 1/2 Completed
NCT00049634 2010-09-16

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

Fred Hutchinson Cancer Center

Phase 1/2 Completed
30 enrolled
NCT00054340 2010-05-14

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Fred Hutchinson Cancer Center

Phase 1/2 Completed